|
Sep 25
|
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
|
|
Sep 23
|
Erasca, Inc. (NASDAQ:ERAS) is favoured by institutional owners who hold 61% of the company
|
|
Aug 29
|
Erasca to Present at Upcoming Investor Conferences in September
|
|
Aug 14
|
We're Hopeful That Erasca (NASDAQ:ERAS) Will Use Its Cash Wisely
|
|
Jun 18
|
Erasca kicks off Phase III trial for naporafenib combo therapy in melanoma
|
|
Jun 18
|
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma
|
|
May 29
|
Erasca to Present at Upcoming Investor Conferences in June
|
|
May 17
|
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
|
|
May 17
|
Erasca Announces Pricing of Underwritten Offering of Common Stock
|
|
May 8
|
Erasca Reports First Quarter 2024 Business Updates and Financial Results
|
|
May 7
|
Erasca to Present at the Bank of America Health Care Conference
|
|
Apr 24
|
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
|
|
Apr 23
|
Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
|
|
Apr 16
|
Institutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year losses
|
|
Apr 1
|
Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript
|
|
Mar 29
|
Erasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ...
|
|
Mar 28
|
Erasca Announces $45 Million Oversubscribed Private Placement Financing
|
|
Mar 27
|
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
|
|
Feb 1
|
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
|
|
Jan 9
|
Is Erasca (NASDAQ:ERAS) In A Good Position To Invest In Growth?
|